0001640334-26-000824
SEC filingQ1 FY2026 reflects a continuation of operational dormancy, with zero revenue and no cost of revenue — consistent with the absence of sales since December 31, 2022 — while losses widened significantly due to fixed public-company compliance costs.
For the three months ended March 31, 2026, Acro Biomedical reported no revenue or cost of revenue — a condition repeated from Q1 FY2025 and directly attributable to the cessation of all sales activity after December 31, 2022. This is not a temporary pause but a sustained operational dormancy: management explicitly states it cannot evaluate the effects of inflation or supply chain issues on pricing or inventory costs because no such transactions have occurred in over three years. The absence of revenue explains why gross profit, gross margin, and related operational metrics are undefined — there is no underlying commercial engine to assess.
Operating income declined to -$60.3K from -$8.9K year-over-year, a deterioration of 574.6%. This widening loss stems entirely from fixed overhead — primarily legal, accounting, and regulatory compliance costs required of a publicly reporting company — rather than any variable cost associated with product development, manufacturing, or distribution. With no sales, no inventory movement, and no customer-facing operations, these expenses represent structural burdens without offsetting income.
Net income followed the same trajectory at -$43.8K (versus -$10.3K YoY), reflecting the absence of tax benefits or non-operating gains and reinforcing that losses are recurring and operationally inert. Diluted EPS remained $0.00, consistent with zero net income and no meaningful share count impact — not an artifact of dilution mechanics, but of total income absence.
Net cash used in operating activities totaled -$49.8K, more than double the -$22.5K used in Q1 FY2025. This acceleration confirms the lack of any revenue-driven cash inflow or working capital recovery — no accounts receivable collections, no inventory liquidation, no vendor payment deferrals. The company continues to rely solely on advances from a minority stockholder, with no binding agreements or assurances of continued funding. Management cautions that solvency hinges entirely on external support remaining available at the provider’s discretion.